Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12967466 | 0.92 | DNM1 (0.46) | MEN1KMT2ACA1DNM1FAAH | |
| SCHEMBL12967471 | 0.90 | DNM1 (0.50) | MEN1KMT2ADNM1FAAH | |
| SCHEMBL12967474 | 0.90 | DNM1 (0.50) | MEN1KMT2ADNM1FAAH | |
| SCHEMBL4886131 | 0.83 | — | — | |
| SCHEMBL16090593 | 0.81 | MEN1 (0.42) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL4374311 | 0.79 | MEN1 (0.44) | MEN1KMT2A | |
| SCHEMBL17327624 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2ATDP1DNM1CA12 | |
| SCHEMBL241252 | 0.79 | MEN1 (0.41) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL23838730 | 0.77 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL856357 | 0.77 | MEN1 (0.40) | MEN1KMT2ATDP1CA1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230227612-A1 | CURABLE COMPOSITION | DAIKIN INDUSTRIES, LTD. (JP) | 2023-07-20 | — | — | US | disclosed |
| US-20230167245-A1 | CURABLE COMPOSITION | DAIKIN INDUSTRIES, LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20220017491-A1 | COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-20 | — | — | US | disclosed |
| EP-3350157-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-2811999-B1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021155267-A2 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2021022173-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLS | MODERNATX, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020227510-A1 | POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2014143799-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8497396-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8247592-B2 | Method of preparing disilanol compound and method of storing disilanol compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| US-20110237546-A1 | METHOD FOR TREATING A MAMMAL BY ADMINISTRATION OF A COMPOUND HAVING THE ABILITY TO RELEASE CO | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUTOS FARMACEUTICOS LDA (PT) | 2011-09-29 | — | — | US | disclosed |
| US-20110218351-A1 | METHOD OF PREPARING DISILANOL COMPOUND AND METHOD OF STORING DISILANOL COMPOUND | SAKANO YASUNORI | 2011-09-08 | — | — | US | disclosed |
| US-7968741-B2 | Method of preparing disilanol compound and method of storing disilanol compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7521158-B2 | Negative dye-containing curable composition, color filter and method of producing the same | FUJIFILM CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | MEN1 366/4885KMT2A 4442/4885TDP1 2098/4885 |
| US-20220017491-A1 | COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT | YAP1, TEAD2, TEAD1 | MEN1 3584/4885KMT2A 2174/4885TDP1 1840/4885 |
| US-20110237546-A1 | METHOD FOR TREATING A MAMMAL BY ADMINISTRATION OF A COMPOUND HAVING THE ABILITY TO RELEASE CO | PTGS1, PTGES, TNF | MEN1 2678/4885KMT2A 4138/4885TDP1 1226/4885 |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | MEN1 2852/4885KMT2A 1077/4885TDP1 2684/4885 |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | MEN1 366/4885KMT2A 4442/4885TDP1 2098/4885 |
| US-20110218351-A1 | METHOD OF PREPARING DISILANOL COMPOUND AND METHOD OF STORING DISILANOL COMPOUND | CBR3, SNRPD3, MSRB3 | MEN1 804/4885KMT2A 1201/4885TDP1 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.